Strategic Partner(s)

Dr. J. Silvio Gutkind: When GPCRs Drive Cancer

GPCRs are the most drugged protein family in medicine, but until recently their role in cancer was treated as marginal — a few curiosities around mas and muscarinic receptors, overshadowed by kinases and Ras. The emergence of cancer genomics has dismantled that framing. Roughly 20% of tumors now show mutations in GPCRs or their coupled G proteins, and specific cancers — uveal melanoma above all — are understood to be driven almost entirely by single hotspot mutations in GαQ.

For Dr. J. Silvio Gutkind, who has spent more than three decades pushing GPCRs as oncogenic signaling systems, the shift has concrete stakes: uveal melanoma patients who metastasize to the liver live six to twelve months, and every pathway his lab has opened — from TRIO and Rho to YAP and FAK — has been an attempt to give those patients something the canonical PLC pathway could not.

In this conversation, Dr. Gutkind traces how GPCRs moved from a side project nobody believed in to a recognized driver class in oncology, and explains why chemokine receptors like CXCR3 may be the next frontier for understanding immunotherapy response.

About the Guest

Dr. J. Silvio Gutkind is Professor of Pharmacology and Associate Director of Basic Science at the UC San Diego Moores Cancer Center. His training began at the University of Buenos Aires on alpha-2 adrenergic receptors, continued at the NIH across neurobiology and oncogenes, and grew into a multi-decade program on GPCR signaling in cancer — first as NIH branch chief at NIDCR, then as head of a team that moved cross-country with him to UCSD in 2015. His lab combines classical pharmacology with cancer genomics, bioinformatics, and synthetic lethality approaches to identify druggable nodes downstream of G protein mutations. Current focuses include GαQ-driven uveal melanoma, GαS mutations across pancreatic, colon, and appendix cancers, and chemokine receptor biology in cancer immunotherapy.

Scientific Themes of the Conversation

GPCRs as oncogenes without mutations — aberrant expression and "oncocrine" autocrine/paracrine signaling
The cancer genomics revolution and the rise of G protein hotspot mutations (GαQ Q209, GαS, Gα13)
GαQ-driven uveal melanoma and the limits of the canonical PLC pathway
Non-canonical GαQ signaling through TRIO, Rho, YAP, and the druggable FAK node
CXCR3 and the chemokine axis that gates immunotherapy response
Structural biology, machine learning, and team science in GPCR pharmacology

Key Insights from the Conversation

1. GPCRs don't need mutations to drive cancer. Aberrant expression — a receptor in the wrong place at the wrong time, paired with autocrine or paracrine ligand — is sufficient to transform cells. Early focus-formation assays using muscarinic receptors and carbachol produced transforming efficiencies comparable to Ras, and the community largely looked away because the biology didn't fit the prevailing mutation-centric frame.

2. Cancer genomics rewrote the role of G proteins. Roughly 20% of tumors carry mutations in GPCRs or G proteins, with striking hotspots in GαQ, GαS, and Gα13. Most large cancer sequencing panels now include these genes — though most oncologists are still unsure what the results mean clinically, leaving a gap between the genomic data and how it's acted upon.

3. The uveal melanoma driver is almost monogenic. Nearly 93% of uveal melanomas carry a single GαQ Q209 activating mutation that blocks GTPase activity. Beyond this driver, the tumor has only a handful of additional mutations — more like a pediatric cancer than an adult one. The canonical assumption that targeting PLC would be therapeutic has failed in the clinic, and patients with liver metastases still have six to twelve months to live.

4. Non-canonical signaling opened a new drug target. A synthetic lethality analysis performed entirely in silico revealed that GαQ tumors depend not only on PLC but on a TRIO → Rho → YAP axis, with FAK emerging as a druggable downstream node. That insight is now powering focal adhesion kinase–directed clinical trials, including one Dr. Gutkind's team is launching.

5. CXCR3 may be the hidden gatekeeper of immunotherapy response. CXCL9, CXCL10, and CXCL11 are among the most robust predictive signatures for checkpoint inhibitor response — and all three are ligands for CXCR3. In knockout mice, loss of CXCR3 abolishes response to both anti-PD-1 and anti-CTLA-4, reframing the receptor as something to activate, not block.

6. "What the heck" moments define real discoveries. Two of Dr. Gutkind's most cited papers came from results that directly contradicted the textbook: βγ subunits (not α) activating ERK through Gi-coupled receptors, and Rho GTPases (not Ras) driving JNK activation. Both required trusting the data when the conceptual framework was telling the team they must be wrong. Both landed in Nature and Cell respectively.

7. Team science is structural, not decorative. The 2020 Cell paper on G protein coupling specificity came from a Gordon Conference hallway conversation, combining bioinformatics from Europe, high-throughput screens from Japan, and biology from UCSD. And the 12 people who moved cross-country from NIH to UCSD did so because of relationships built over years — a retention outcome Dr. Gutkind attributes to the team, not the weather.

Selected Quotes

"The very simple concept is that GPCRs do not need to be mutated to be oncogenic."

"There are cancers that are driven by G proteins. That changed the landscape in terms of understanding and appreciation."

"What the heck — this doesn't make sense. And that was our first Cell paper. Still our most cited paper."

"Don't be afraid to send emails."

Episode Timeline

00:00 Introduction
02:09 From Buenos Aires to NIH: a career that followed the science, not the field
06:19 Operation Exodus — the team that moved cross-country
07:35 The muscarinic focus assay and a side project no one believed in
10:52 The cancer genomics result that reframed GPCRs as drivers
16:45 Why CXCR3 may decide who responds to checkpoint inhibitors
20:28 GαQ, uveal melanoma, and the failure of the textbook pathway
41:27 Structural biology, machine learning, and the coupling problem
45:31 Two "what the heck" moments that became Nature and Cell papers
50:48 Advice for young scientists — read, think, question the dogma
56:33 Why small conferences produce the best collaborations

Timestamps were generated using AI for readability.

About this episode

Have you had moments that defined your scientific tastes? For Dr. J Silvio Gutkind, a class on oncogenes and his interests for GPCRs helped shape his scientific interests. These took him from the University of Buenos Aires in Argentina to UC San Diego and through the National Institutes of Health in Bethesda, Maryland. In this episode, Silvio discusses G protein signaling in the context of cancer, immunotherapies, and combination therapies that could help improve patients’ lives.

Dr. J. Silvio Gutkind on the web